MBIO · Insider Trading
Mustang Bio, Inc.
Every open-market purchase and sale reported by MBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-27 | Manuel MD Litchman | President, CEO and Interim CFO | F | −19 | −$14 |
| 2026-01-05 | Fortress Biotech, Inc. | 10%+ Owner | A | +278,385 | — |
| 2025-12-30 | Adam J. Chill | Director | Sell | −4 | −$4 |
| 2025-12-30 | Neil Herskowitz | Director | Sell | −247 | −$238 |
| 2025-12-30 | David Jin | Director | Buy | +247 | +$238 |
| 2025-10-01 | Fortress Biotech, Inc. | 10%+ Owner | A | +59,334 | — |
| 2025-04-28 | Manuel MD Litchman | President, CEO and Interim CFO | F | −27 | −$33 |
| 2025-04-02 | Fortress Biotech, Inc. | 10%+ Owner | A | +67,806 | — |
| 2024-06-28 | Fortress Biotech, Inc. | 10%+ Owner | A | +575,191 | — |
| 2024-06-04 | Manuel MD Litchman | President and CEO | F | −1,396 | −$489 |
| 2024-06-04 | Manuel MD Litchman | President and CEO | F | −2,820 | −$21.78K |
| 2024-01-03 | Fortress Biotech, Inc. | 10%+ Owner | A | +419,092 | — |
| 2023-07-07 | Adam J. Chill | Director | A | +7,246 | — |
| 2023-07-07 | Michael J Zelefsky | Director | A | +7,246 | — |
| 2023-07-07 | Manuel MD Litchman | President and CEO | A | +5,000 | — |
| 2023-07-07 | Neil Herskowitz | Director | A | +7,246 | — |
| 2023-07-07 | Lindsay A Md Rosenwald | Director | A | +7,246 | — |
| 2023-07-07 | Michael S Weiss | Director | A | +7,246 | — |
| 2023-04-03 | Adam J. Chill | Director | A | +71,664 | — |
| 2023-04-03 | Manuel MD Litchman | Director | MIXED | +71,000 | +$6.28K |
| 2023-04-03 | Michael S Weiss | Director | A | +71,664 | — |
| 2023-04-03 | Lindsay A Md Rosenwald | Director | MIXED | +80,758 | +$5.61K |
| 2023-04-03 | Neil Herskowitz | Director | A | +71,664 | — |
| 2023-04-03 | Michael J Zelefsky | Director | A | +71,664 | — |
| 2023-01-06 | Fortress Biotech, Inc. | 10%+ Owner | A | +2,807,008 | — |
| 2021-12-16 | Brian Achenbach | SVP, Fin. & Corp. Controller | MIXED | +18,126 | −$8.00K |
| 2021-11-08 | Manuel MD Litchman | President and CEO | Buy | +65,000 | +$145.60K |
| 2021-10-21 | Brian Achenbach | SVP, Fin. & Corp. Controller | Sell | −4,450 | −$10.15K |
| 2021-09-24 | Manuel MD Litchman | President and CEO | A | +2,746 | +$7.08K |
| 2021-09-24 | Lindsay A Md Rosenwald | Director | A | +1,170 | +$3.02K |
| 2021-08-05 | Manuel MD Litchman | President and CEO | Buy | +86,206 | +$250.86K |
| 2021-07-08 | Manuel MD Litchman | President and CEO | A | +61,000 | — |
| 2021-07-08 | Lindsay A Md Rosenwald | Director | A | +13,774 | — |
| 2021-07-08 | Neil Herskowitz | Director | A | +13,774 | — |
| 2021-07-08 | Adam J. Chill | Director | A | +13,774 | — |
| 2021-07-08 | Michael S Weiss | Director | A | +13,774 | — |
| 2021-07-08 | Michael J Zelefsky | Director | A | +13,774 | — |
| 2021-04-29 | Manuel MD Litchman | President and CEO | Sell | −12,373 | −$37.61K |
| 2021-04-16 | Brian Achenbach | SVP, Fin. & Corp. Controller | Sell | −20,721 | −$66.28K |
| 2021-03-15 | Brian Achenbach | SVP, Fin. & Corp. Controller | A | +22,500 | — |
| 2021-03-15 | Lindsay A Md Rosenwald | Director | A | +1,043 | +$2.95K |
| 2021-03-15 | Manuel MD Litchman | President and CEO | MIXED | +170,562 | +$530.70K |
| 2020-12-22 | Lindsay A Md Rosenwald | Director | MIXED | +101,182 | +$268.93K |
| 2020-12-22 | Lindsay A Md Rosenwald | Director | A | +17,442 | +$43.26K |
| 2020-12-22 | Manuel MD Litchman | President and CEO | MIXED | +166,000 | +$303.40K |
| 2020-12-15 | Lindsay A Md Rosenwald | Director | Buy | +100,000 | +$266.00K |
| 2020-08-19 | Lindsay A Md Rosenwald | Director | A | +16,611 | — |
| 2020-08-19 | Adam J. Chill | Director | A | +16,611 | — |
| 2020-08-19 | Michael J Zelefsky | Director | A | +16,611 | — |
| 2020-08-19 | Neil Herskowitz | Director | A | +16,611 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Fortress Biotech, Inc. | 10%+ Owner | 536,577 | $193.22K |
| Manuel MD Litchman | President, CEO and Interim CFO | 1,615 | $582 |
| Adam J. Chill | Director | 375 | $135 |
| David Jin | Director | 286 | $103 |
| Neil Herskowitz | Director | 145 | $52 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.